Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06568237 · ClinicalTrials.gov registry record · Phase 2
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
A Phase 2 study of Multiple System Atrophy, sponsored by Teva Branded Pharmaceutical Products R&D.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT06568237: Recruiting Phase 2 study of Multiple System Atrophy, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT06568237 is a Phase 2 study of Multiple System Atrophy that is actively recruiting participants, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 350 participants, above the 257-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (36% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06568237, a Phase 2 study of Multiple System Atrophy, is actively recruiting participants, sponsored by Teva Branded Pharmaceutical Products R&D.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned study period per participant is 56 weeks including a screening period (up to 4 weeks), a 48-week double-blind treatment period, and a follow-up visit (approximately 4 weeks after the end of the double-blind treatment period). The study duration will be approximately 27 months.
Primary Outcome
The UMSARS is a multidimensional, validated scale for semi-quantitative clinical assessments of MSA participants. Modified UMSARS part I includes all items with the exclusion of item 11. Item scoring is scaled 0-3 using a range of 0 (no impairment) to 3 (severe impairment).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TEV-56286
Study Locations (20)
California
- Teva Investigational Site 15554 - La Jolla
- Teva Investigational Site 15545 - Los Angeles
Florida
- Teva Investigational Site 15544 - Boca Raton
- Teva Investigational Site 15555 - Tampa
New York
- Teva Investigational Site 15549 - New York
- Teva Investigational Site 15551 - New York
Pennsylvania
- Teva Investigational Site 15735 - Hershey
- Teva Investigational Site 15548 - Pittsburgh
Other
- Teva Investigational Site 35290 - Bordeaux
- Teva Investigational Site 35289 - Marseille
District of Columbia
- Teva Investigational Site 15547 - Washington D.C.
Illinois
- Teva Investigational Site 15550 - Chicago
Kansas
- Teva Investigational Site 15546 - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2024-10-02 |
| Est. Completion | 2027-09-15 |
| Phase | Phase 2 |
What NCT06568237 shows while recruiting
NCT06568237 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, above the 257-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (36% higher).
The record links to 1 condition, with Multiple System Atrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06568237 names 20 study sites across 15 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06568237 about?
NCT06568237 is a clinical study titled "A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy". The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to...
What is the current status of trial NCT06568237?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2024-10-02. Estimated completion is 2027-09-15.
What conditions does trial NCT06568237 study?
This clinical trial studies the following conditions: Multiple System Atrophy.
What interventions are being tested in trial NCT06568237?
The interventions under investigation include: Placebo (DRUG), TEV-56286 (DRUG).
Who is sponsoring clinical trial NCT06568237?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06568237 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple System Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06568237's enrollment target sits among peer trials
350 9th of 30 higher than 22 of 30 other Multiple System Atrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple System Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
RECRUITING · Phase 2
-
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
RECRUITING · Phase 2
-
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
RECRUITING · Phase 2
-
A Study of Lu AF82422 in Participants With Multiple System Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI